Compare Noble Corporation plc (NE) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs Viatris Inc — how do they compare? Noble Corporation plc trades at $42.34 (market cap $6.73B), while Viatris Inc trades at $17.41 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 3× Noble Corporation plc's market cap, and Noble Corporation plc pays the higher dividend (4.74%). Which is the better fit depends on your goals — on Pluang, investors hold Noble Corporation plc for 26 Days and Viatris Inc for 57 Days on average.
| NE | VTRS | |
|---|---|---|
Market Cap | $6.73B | $20.03B |
Volume | 1,027,635 | 14,109,977 |
Sector | Energy | Health |
52-Week High | $54.37 | $18.27 |
52-Week Low | $26.70 | $9.74 |
Typical Hold Time | 26 Days | 57 Days |
Enterprise Value | $8.16B | $32.15B |
Dividend Yield | 4.74% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $42.21, up 3.03% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported declining revenue from $3.29B in 2025 to $3.1B in 2026, with net income dropping from $217M to $150M. Recent positive developments include securing a long-term drilling contract in Ghana, though earnings have been inconsistent with two misses and one beat in the last four quarters.
The stock presents a cautious opportunity with analyst consensus target of $52.00 offering 23% upside, but faces headwinds from declining profitability and ongoing SEC investigation. Investors should weigh the contract wins against execution risks and margin pressure in the offshore drilling sector.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
